# Pizarra — PT-pseudo_48fb60dfd22f (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_48fb60dfd22f
Task: 1

Encounter: Urology - outpatient on 14 Feb 2025.
Referrer: Dr. T. Hendriks (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 24.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.986 ng/mL²
  - PSA velocity: 3.9 ng/mL/yr
  - Prior PSA: 16.9 ng/mL
  - Prostate volume: 24.35 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8596296 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Osteoarthritis
  - Problem list / PMHx: Hypertension, Osteoarthritis
  - Current medication: metoprolol, paracetamol PRN
  - Allergies: NKA
  - Additional notes: PSA 24 ng/mL. PI-RADS 5. PSAD 0.99. Prostate volume 24 mL. csPCa 0.86.

Vitals: weight 93 kg, height 189 cm, BMI 26.0, BP 130/73 mmHg, HR 68 bpm. Smoking: Non-smoker.

Chief complaint: Clinical reassessment sought after mpMRI acquisition and a PSA increase reaching 24.0 ng/mL.

History: A 68-year-old mechanical engineer initiated evaluation in September 2022 due to an elevated PSA reading. He is a non-smoker, and his prior biopsy bucket remains None. Long-standing hypertension is managed with metoprolol, while osteoarthritis discomfort is addressed with paracetamol taken only when necessary. He shares a home with his wife, and adult offspring stop by every week, with their son handling administrative correspondence. Moderate lower urinary tract symptoms produce an IPSS total of 12. A stable cardiology assessment occurred during autumn 2024, accompanied by routine thyroid and vascular checks. Joint stiffness limits his mobility, necessitating a walking frame for extended distances and a ground-floor consultation room. He explicitly denies unexplained weight loss, osseous pain, or nocturnal diaphoresis.

Physical examination: DRE — texture: symmetrically smooth; mobility: unrestricted; asymmetry: absent. The glandular surface presents without palpable nodules, aligning with a normal digital examination. General inspection notes a well-nourished individual in no acute distress, registering a BMI of 26.0. Hemodynamic parameters remain stable at 130/73 mmHg with a regular pulse of 68 bpm. Cardiovascular and respiratory auscultation yield unremarkable results.

Patient info: mechanical engineer; Married; Lives with partner; adult children visit weekly.
Next of kin: Adult son (primary contact).

Lifestyle: alcohol 18 units / week; exercise Running 3x/week, 5 km; IPSS score: 12/35 (moderate LUTS).

Recent other appointments: Endocrine — thyroid screening; Vascular surgery — varicose veins consult; Cardiology — annual review (stable, autumn 2024).
Admin: Mobility limitation (frame); ground-floor consult room preferred.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.82 +/- 0.14   (95% CI 0.46-0.99)

Where the uncertainty comes from:
  - aleatoric  dA = 0.13  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.07  (few labelled cases resemble this one)
  - 6.4 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'firm': A +/- 1.96*dA does not cross the 0.5 threshold. On the 91 labelled cases this tier was never wrong, but it only covered 17 of them, so the 95% CI on that accuracy still reaches down to ~0.75. Treat it as a strong prior that should only be overturned by explicit contradicting evidence.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=0.0, psa=24.0, age=68.0, psad=0.986, dre_ord=0.0, vol=24.35, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the specific PSA velocity (3.9 ng/mL/yr) or the full PSA history trend, which is critical given the high PSA level (24.0 ng/mL) and the prior PSA (16.9 ng/mL). It also missed the context provided by the mpMRI report prose and the full laboratory panel, which might contain markers influencing the csPCa probability or risk stratification beyond the basic metrics.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests biopsy (0.82), but the patient has a prior biopsy status of "None". This means the question "does he have cancer" is being asked for the first time based on a high PI-RADS 5 and high csPCa probability (0.86). The prior does not account for the fact that a prior negative biopsy (if one existed) would change the question, but here the prior is based on a 'None' status. Furthermore, the PSA velocity of 3.9 ng/mL/yr is a significant dynamic feature that the prior did not explicitly incorporate, potentially leading to an overestimation of the probability of cancer compared to a stable PSA.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> -> radiology / mpMRI report -> If the prose suggests a clinically significant finding contradicting the PI-RADS 5, it could lower the decision threshold.
  <document> -> PSA history (trend) -> If the trend is flat or decreasing despite the high PSA, it would temper the urgency for biopsy.
  <document> -> laboratory results (full panel) -> If specific markers (e.g., PSA density context) suggest a lower risk profile, it could reduce the probability of biopsy.
  <document> -> previous GP / urology consultation notes -> To see if prior concerns or LUTS severity provide context for the current high PSA.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number. If a document turned out to be uninformative, say so in one line.

  **radiology / mpMRI report**
  Tergooi MC Radiology | 10 February 2025 | mpMRI Prostate
  Clinical indication: Evaluation of a 68-year-old gentleman with a progressive PSA trajectory (17.8 to 24.0 ng/mL) alongside moderate lower urinary tract symptoms. Study requested for anatomical localisation and staging.
  FINDINGS:
  Glandular volume measures 24.35 mL. Architectural symmetry is disrupted. A discrete focus occupies the right peripheral zone at the mid-gland posterior aspect, spanning 14 x 11 x 10 mm. T2-weighted sequences display profound hypointensity with obliteration of typical zonal boundaries. Diffusion mapping reveals severe signal restriction (b-value 1400) paired with depressed ADC values. Post-contrast dynamics demonstrate rapid, robust, and sustained uptake compared to surrounding tissue. Extracapsular spread and seminal vesicle involvement are absent. The prostatic capsule maintains continuity. Pelvic lymph nodes show no suspicious characteristics. Bladder and rectal mucosa appear normal.
  IMPRESSION:
  PI-RADS 5 lesion located in the right mid-peripheral zone.
  Prostate volume 24.35 mL.
  PSAD 0.986 ng/mL/mL.
  csPCa predicted probability 0.8596296.

  **PSA history**
  {"case_id": "PT-pseudo_48fb60dfd22f", "psa_trend": [{"date": "Sep 2022", "val": 11.8}, {"date": "Dec 2023", "val": 9.8}, {"date": "Feb 2025", "val": 24.0}]}

  **laboratory results**
  {"case_id": "PT-pseudo_48fb60dfd22f", "laboratory_results": [{"name": "PSA", "val": "24.0 ng/mL", "date": "12 Jan 2025", "flag": "H"}, {"name": "Free PSA", "val": "2.48 ng/mL", "date": "12 Jan 2025", "flag": ""}, {"name": "%Free PSA", "val": "10%", "date": "12 Jan 2025", "flag": "L"}, {"name": "Haemoglobin", "val": "14.5 g/dL", "date": "12 Jan 2025", "flag": ""}, {"name": "WBC", "val": "7.6 x10^9/L", "date": "12 Jan 2025", "flag": ""}, {"name": "Platelets", "val": "232 x10^9/L", "date": "12 Jan 2025", "flag": ""}, {"name": "Creatinine", "val": "97 umol/L", "date": "12 Jan 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "12 Jan 2025", "flag": ""}, {"name": "Testosterone", "val": "14.2 nmol/L", "date": "12 Jan 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "87 U/L", "date": "12 Jan 2025", "flag": ""}, {"name": "LDH", "val": "145 U/L", "date": "12 Jan 2025", "flag": ""}, {"name": "HbA1c", "val": "6.3 %", "date": "12 Jan 2025", "flag": ""}]}

  **previous GP / urology consultation notes**
  {"case_id": "PT-pseudo_48fb60dfd22f", "previous_notes": [{"date": "20 Feb 2024", "author": "Dr. T. Hendriks (GP)", "text": "Clinical review conducted during the annual health assessment. December 2023 testing recorded a PSA level of 16.9 ng/mL, reflecting a minor decline from the 17.8 ng/mL documented in September 2022. Persistent elevation alongside advanced age coincided with a multiparametric scan order and a specialist referral. Current regimen includes metoprolol for adequately controlled hypertension."}, {"date": "19 Jun 2024", "author": "Dr. T. Hendriks (GP)", "text": "Subsequent discussion addressed the pending specialist consultation. Imaging data returned indicating a highly suspicious focus. Referral documentation was advanced to the urology department. Lower urinary tract symptoms remain steady, yielding an IPSS score of 12. Autumn 2024 cardiology evaluation proved unremarkable."}]}

NOT RETRIEVED
  get_family_history - Not called as per retrieval economy rules.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  PI-RADS 5 lesion located in the right mid-peripheral zone.
  PSA velocity of 3.9 ng/mL/yr.
  csPCa predicted probability 0.8596296.
  Rapid, robust, and sustained uptake on post-contrast dynamics.

  AGAINST sampling this patient now:
  %Free PSA 10% (which is generally a favorable marker).

WHERE THIS LEANS
  The retrieved evidence strongly supports sampling due to the high-risk MRI finding (PI-RADS 5), the high PSA velocity, and the high predicted cancer probability. This confirms the statistical prior's suggestion of BIOPSY, as the dynamic and imaging data align with a high-risk profile.

[Sections actually revealed in this consultation: psa_trend, radiology_report, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended due to the convergence of high-risk features: a PI-RADS 5 lesion, a significant PSA velocity of 3.9 ng/mL/yr, and a high csPCa predicted probability of 0.8596296. The statistical prior suggested biopsy, and the retrieved evidence strongly supports this by highlighting the dynamic imaging findings and high risk profile. The favorable %Free PSA of 10% is outweighed by these aggressive indicators.

Variables that carried weight: age=noted, psa=decisive, vol=noted, psad=important, cspca=important, pirads=decisive, comorbidity=noted
Sections revealed: psa_trend, radiology_report, laboratory_results, previous_notes
